Leo Cancer Care, a medical technology company focused on reimagining cancer treatment, has successfully closed an oversubscribed Series D financing round, raising £51 million ($65 million). The significant investment, led by Silicon Valley's Yu Galaxy and including new investor Eventide Asset Management, alongside continued support from existing backers, will be used to scale manufacturing, accelerate commercial deployment, and further develop its integrated upright cancer care platform.
The company's innovative approach centres on designing imaging and treatment systems around the human body's natural upright position. This method is supported by growing global research suggesting it may lead to more consistent anatomical positioning and organ stability compared to traditional supine (lying-down) treatments. The integrated platform aims to provide a unified approach to cancer care, from diagnosis and planning through to treatment, across proton therapy, photon therapy, and imaging modalities.
A notable milestone for Leo Cancer Care occurred on 4 June 2026, when Stanford Medicine delivered the world's first compact upright proton therapy treatment. This historic procedure involved treating a seven-year-old child with a complex brain tumour using Leo's Marie® platform. By rotating the seated patient rather than a multi-tonne gantry, the Marie® system allows for a proton therapy room that is approximately five times smaller than conventional setups, potentially enabling advanced care to be installed in existing radiotherapy vaults and brought closer to patients.
Leading cancer institutions, including Dana-Farber Cancer Institute and McLaren Health Care, are already integrating the upright platform into their programmes. This adoption spans both world-leading academic centres and smaller, community-based networks, indicating a growing recognition of the potential benefits of this technology. The platform's upright imaging system has already received FDA clearance, with future applications planned across general radiology in addition to its role in treatment planning and delivery.
Alongside the financing, Leo Cancer Care has announced a major strategic partnership with an international healthcare giant. This collaboration signals increasing interest from major industry players in the upright cancer care paradigm, with further details expected to be announced in the coming weeks. Stephen Towe, CEO and Co-Founder of Leo Cancer Care, stated that the aim is to reimagine how care is delivered, making advanced treatment accessible to communities without compromising quality.